JP5415771B2 - 新規なエポプロステノール製剤およびその製造方法 - Google Patents
新規なエポプロステノール製剤およびその製造方法 Download PDFInfo
- Publication number
- JP5415771B2 JP5415771B2 JP2008553381A JP2008553381A JP5415771B2 JP 5415771 B2 JP5415771 B2 JP 5415771B2 JP 2008553381 A JP2008553381 A JP 2008553381A JP 2008553381 A JP2008553381 A JP 2008553381A JP 5415771 B2 JP5415771 B2 JP 5415771B2
- Authority
- JP
- Japan
- Prior art keywords
- solution
- epoprostenol
- diluent
- arginine
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960001123 epoprostenol Drugs 0.000 title claims description 67
- 239000000203 mixture Substances 0.000 title claims description 57
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 238000009472 formulation Methods 0.000 title description 35
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 title 1
- LMHIPJMTZHDKEW-XQYLJSSYSA-M Epoprostenol sodium Chemical compound [Na+].O1\C(=C/CCCC([O-])=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 LMHIPJMTZHDKEW-XQYLJSSYSA-M 0.000 claims description 102
- 239000000243 solution Substances 0.000 claims description 66
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 39
- 239000004475 Arginine Substances 0.000 claims description 32
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 28
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 26
- 229930195725 Mannitol Natural products 0.000 claims description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 26
- 239000008364 bulk solution Substances 0.000 claims description 26
- 239000000594 mannitol Substances 0.000 claims description 26
- 235000010355 mannitol Nutrition 0.000 claims description 26
- 239000003085 diluting agent Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 14
- 239000012895 dilution Substances 0.000 claims description 13
- 238000010790 dilution Methods 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 13
- 238000004108 freeze drying Methods 0.000 claims description 11
- -1 hydroxylethyl Chemical group 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 239000008215 water for injection Substances 0.000 claims description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- 239000004067 bulking agent Substances 0.000 claims description 9
- 229960003013 epoprostenol sodium Drugs 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 8
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 claims description 8
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 7
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 229920002307 Dextran Polymers 0.000 claims description 6
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 6
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 5
- 206010002383 Angina Pectoris Diseases 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 238000007865 diluting Methods 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 239000012299 nitrogen atmosphere Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 14
- 238000001990 intravenous administration Methods 0.000 description 12
- 230000008569 process Effects 0.000 description 11
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 230000003113 alkalizing effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 150000007529 inorganic bases Chemical class 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000006037 cell lysis Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000008181 tonicity modifier Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 150000004679 hydroxides Chemical class 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000012792 lyophilization process Methods 0.000 description 3
- 239000012931 lyophilized formulation Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000003284 homeostatic effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000012545 Psychophysiologic disease Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical group C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 108091008698 baroreceptors Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940001440 flolan Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052806 inorganic carbonate Inorganic materials 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000001774 pressoreceptor Anatomy 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Description
1. 約0.5〜0.7℃/分の速度で約−30℃以下に棚を冷却させ、約30〜45分間にわたりまたは生成物の温度が約−25℃以下に達するまで棚をこの温度に保持する工程。
2. 生成物の温度が約−38±2℃以下に達するまで棚温度を約−45℃±2℃以下に低下させる工程。
3. 約6時間以上にわたり生成物をこの温度に保持する工程。
4. チャンバー圧力が50ミリトール以下の領域に達するまで真空を適用する工程。
5. 真空適用後も約45分間以上にわたり棚温度を約−45±2℃に保持する工程。
1. 真空下に保持しながら約20±2℃/時の加熱速度で約0℃±2℃に棚温度を上昇させ、生成物温度が約−3±2℃以上に達するまで乾燥を継続する工程。
2. 真空下に保持しながら約25±2℃に棚温度を上昇させて乾燥サイクルを継続し、生成物の温度が約20±2℃以上に達するまで乾燥を継続する工程。
現在市販されているエポプロステノールの一形態(フローラン)の安定性を理解するために、本発明者らは、凍結乾燥されたエポプロステノール入りバイアルおよび希釈剤を、Physician’s Desk Reference(PDR)に記載の組成に従って調製した。注射用フローランは、静脈内(IV)投与に供すべく製剤化された滅菌ナトリウム塩である。凍結乾燥されたフローラン入りバイアルはそれぞれ、0.5mgまたは1.5mgのエポプロステノールと等価なエポプロステノールナトリウム、3.76mgのグリシン、2.93mgの塩化ナトリウム、および50mgのマンニトールを含む。pHを調整するために水酸化ナトリウムが添加されていることもある。本発明者らは、この処方を用いてフローラン模擬製品を作製した。
エポプロステノールと50mg/mlのアルギニンとを含む溶液を調製し、5℃におけるこの溶液の安定性を調べた。得られたデータを表4に示す。
次の一連の実験では、エポプロステノールおよびアルギニンを含む溶液のpHを水酸化ナトリウムで13.0に調整し、凍結乾燥させた。1mlの注射用水で凍結乾燥物を再構成した後、再構成溶液は、50mg/mlのアルギニンおよび0.5mg/mlのエポプロステノールを含む。溶液のpHは13.0である。安定性データを5℃については表6に、29℃については以下の表7に示す。
次の開発段階で、本発明者らは、凍結乾燥用のバルク溶液のpHを10.5〜13.0に調整して異なる賦形剤の存在下でいくつかの凍結乾燥製剤をスクリーニングした。試験製剤の組成を表8に詳細に示し、安定性データを以下の表9にまとめる。
1. 1バイアルあたりエポプロステノール(0.5mg)/アルギニン(50mg)/マンニトール(50mg)/pH13を含むものを3バッチ
2. 1バイアルあたりエポプロステノール(0.5mg)/アルギニン(50mg)/マンニトール(50mg)/pH12を含むものを1バッチ
3. 1バイアルあたりエポプロステノール(0.5mg)/アルギニン(50mg)/トレハロース(50mg)/pH13を含むものを2バッチ
4. 1バイアルあたりエポプロステノール(0.5mg)/アルギニン(50mg)/トレハロース(50mg)/pH12を含むものを1バッチ
5. pH12および13に調整されたフローラン組成物を含むものを1バッチずつ。
これらの各バッチの湿分含有率は、7〜10%の範囲内であった。
本発明に係る製剤が室温におけるIV注入に適しているかを調べるために、希釈試験をも行った。種々の大量非経口溶液剤中において24時間にわたる注入時の温度を模倣すべく25℃および30℃で安定性試験を行った。
乳酸加リンゲル液中における希釈安定性についても調べ、以下の表29〜30に示した。
Claims (26)
- (a)(i)エポプロステノールまたはその塩と(ii)アルギニンとを含むバルク溶液を提供する工程と、
(b)前記バルク溶液のpHを13以上に調整する工程と、
を含み、
前記工程(b)が、水酸化ナトリウムおよび水酸化カリウムの少なくとも1種を添加することにより達成される、エポプロステノール組成物の製造方法。 - (c)前記バルク溶液を凍結乾燥させる工程をさらに含む、請求項1に記載の方法。
- 工程(c)が凍結サイクルとそれに続く一次乾燥サイクルおよび二次乾燥サイクルとを含む、請求項2に記載の方法。
- 前記凍結サイクルが、
(i)凍結乾燥チャンバー内の棚上に前記バルク溶液を配置する工程と、
(ii)約0.5〜0.7℃/分の速度で−30℃以下に前記棚を冷却させる工程と、
(iii)30〜45分間にわたりまたは前記バルク溶液の温度が−25℃以下に達するまで−30℃以下に保持する工程と、
(iv)前記バルク溶液の温度が−38±2℃に達するまで前記棚の温度を−45±2℃に低下させる工程と、
(v)前記バルク溶液を6時間以上にわたり−38±2℃に保持する工程と、
(vi)前記チャンバーの圧力が50ミリトール以下に達するまで真空を適用する工程と、
(vii)真空適用後45分間以上にわたり前記棚の温度を−45±2℃に保持する工程と、
を含む、請求項3に記載の方法。 - 前記一次乾燥サイクルが、
(i)毎時20±2℃の加熱速度で0±2℃に前記棚の温度を上昇させ、生成物の温度が−3±2℃以上に達するまで真空下で乾燥を継続する工程と、
(ii)25±2℃に前記棚の温度を上昇させ、前記生成物の温度が20℃以上に達するまで乾燥を継続する工程と、
を含む、請求項3に記載の方法。 - 前記二次乾燥サイクルが、
(i)3±2℃/時の速度で45±2℃に前記棚の温度を上昇させ、前記生成物の温度が38±2℃以上に達するまで乾燥を継続する工程と、
(ii)前記チャンバーの圧力を窒素で増加させながら真空を解除する工程と、
(iii)前記チャンバーの圧力が大気圧に達した場合、窒素ブリーディングを中断し、窒素雰囲気下に前記組成物を閉じ込める工程と、
を含む、請求項3に記載の方法。 - エポプロステノールまたはその塩とアルギニンとの比が1:25〜1:200である、請求項1に記載の方法。
- 前記バルク溶液が増量剤をさらに含む、請求項1に記載の方法。
- 前記増量剤が、ヒドロキシルエチルデンプン(HES)、ソルビトール、ラクトース、デキストラン、マルトース、マンノース、リボース、スクロース、マンニトール、トレハロース、ラクトース、デキストラン、シクロデキストリン、グリシン、およびポリビニルピロリジン(PVP)からなる群から選択される、請求項8に記載の方法。
- 前記増量剤が1〜10%の割合で存在する、請求項8に記載の方法。
- 前記塩がエポプロステノールナトリウムである、請求項1に記載の方法。
- (d)第1の希釈剤で前記バルク溶液を希釈する工程、をさらに含む、請求項1に記載の方法。
- 前記工程(d)において、希釈された前記バルク溶液を第2の希釈剤で希釈することをさらに含む、請求項12に記載の方法。
- 前記第2の希釈剤は、生理食塩水または乳酸加リンゲル液である、請求項13に記載の方法。
- (a)エポプロステノールまたはその塩と、(b)アルギニンと、(c)水と、水酸化ナトリウムおよび水酸化カリウムの少なくとも1種と、を含み、13超のpHを有する、安定な溶液。
- エポプロステノールナトリウムとアルギニンとの比が1:25〜1:200である、請求項15に記載の溶液。
- 増量剤をさらに含む、請求項15に記載の溶液。
- 前記増量剤が、ヒドロキシルエチルデンプン(HES)、ソルビトール、ラクトース、デキストラン、マルトース、マンノース、リボース、スクロース、マンニトール、トレハロース、ラクトース、デキストラン、シクロデキストリン、グリシン、およびポリビニルピロリジン(PVP)からなる群から選択される、請求項17に記載の溶液。
- 前記増量剤が1〜10%の割合で存在する、請求項17に記載の溶液。
- 前記塩がエポプロステノールナトリウムである、請求項15に記載の溶液。
- アテローム硬化症、動脈硬化症、鬱血性心不全、狭心症、および高血圧症からなる群から選択される疾患の治療用の薬剤を製造するための、請求項15に記載の溶液の、使用。
- 再構成溶液を形成するために、第1の希釈剤で前記溶液を再構成することをさらに含む、請求項21に記載の使用。
- 前記第1の希釈剤が、注射用水、0.9%塩化ナトリウム溶液、乳酸加リンゲル液、リンゲル液、炭酸ナトリウム溶液、または重炭酸塩溶液である、請求項22に記載の使用。
- 希釈溶液を形成するために第2の希釈剤で前記再構成溶液を希釈することをさらに含む、請求項22に記載の使用。
- 前記希釈溶液が血液適合性である、請求項24に記載の使用。
- 前記再構成溶液が自己保存される、請求項22に記載の使用。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76476906P | 2006-02-03 | 2006-02-03 | |
US60/764,769 | 2006-02-03 | ||
US77256306P | 2006-02-13 | 2006-02-13 | |
US60/772,563 | 2006-02-13 | ||
US78342906P | 2006-03-20 | 2006-03-20 | |
US60/783,429 | 2006-03-20 | ||
PCT/US2007/002948 WO2007092343A2 (en) | 2006-02-03 | 2007-02-02 | Novel epoprostenol formulation and method of making thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009525344A JP2009525344A (ja) | 2009-07-09 |
JP5415771B2 true JP5415771B2 (ja) | 2014-02-12 |
Family
ID=38345694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008553381A Active JP5415771B2 (ja) | 2006-02-03 | 2007-02-02 | 新規なエポプロステノール製剤およびその製造方法 |
Country Status (14)
Country | Link |
---|---|
US (2) | US8318802B2 (ja) |
EP (1) | EP1993557B1 (ja) |
JP (1) | JP5415771B2 (ja) |
KR (1) | KR101351668B1 (ja) |
CN (1) | CN101410119B (ja) |
BR (1) | BRPI0707488B8 (ja) |
CA (2) | CA2868998A1 (ja) |
DK (1) | DK1993557T3 (ja) |
ES (1) | ES2558705T3 (ja) |
HU (1) | HUE026166T2 (ja) |
PL (1) | PL1993557T3 (ja) |
PT (1) | PT1993557E (ja) |
SI (1) | SI1993557T1 (ja) |
WO (1) | WO2007092343A2 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE026166T2 (en) | 2006-02-03 | 2016-05-30 | Actelion Pharmaceuticals Ltd | New epoprosthenol preparation and procedure |
EP2200650B1 (en) * | 2007-09-07 | 2016-01-06 | United Therapeutics Corporation | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
AU2010280684B2 (en) * | 2009-08-07 | 2016-07-28 | Scipharm Sarl | Composition for the treatment of cystic fibrosis |
CN101669904B (zh) * | 2009-09-29 | 2011-06-22 | 北京中海康医药科技发展有限公司 | 一种依前列醇脂质纳米粒及制备方法 |
US20120321728A1 (en) * | 2011-06-15 | 2012-12-20 | Ven Subbiah | Nutritional formula for managing angina pectoris |
JP5917034B2 (ja) * | 2011-07-15 | 2016-05-11 | ニプロ株式会社 | カルシウムブロッカーを含有する固形医薬組成物 |
CN103585119A (zh) * | 2013-11-13 | 2014-02-19 | 北京泰德制药股份有限公司 | 一种包含依前列醇及其药用盐的稳定化制剂及其制备方法 |
ITMI20142149A1 (it) * | 2014-12-16 | 2016-06-16 | L I A Di Giuseppe Capasso | Apparato di diagnosi differenziale in medicina adattato per determinare la sequenza di test ottimale atta ad identificare una patologia secondo criteri di appropriatezza diagnostica |
HU231031B1 (hu) | 2016-03-23 | 2019-12-30 | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. | Megnövelt stabilitású epoprostenol nátrium és eljárás előállítására |
CN110381951A (zh) | 2016-12-14 | 2019-10-25 | 瑞必治公司 | 用于治疗肺性高血压和其他肺病症的方法及组合物 |
CN109330982A (zh) * | 2018-09-13 | 2019-02-15 | 常州市第四制药厂有限公司 | 依前列醇冻干粉及其制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2021581B (en) | 1978-05-17 | 1982-10-20 | Wellcome Found | Stabilisation of pgl derivatives |
ZA787353B (en) | 1978-05-17 | 1980-08-27 | Wellcome Found | Pharmaceutical formulations |
US7230014B1 (en) | 1997-10-14 | 2007-06-12 | Eisai Co., Ltd. | Pharmaceutical formulation comprising glycine as a stabilizer |
US6803386B2 (en) * | 2002-01-16 | 2004-10-12 | United Therapeutics Corporation | Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer |
DE10225551A1 (de) * | 2002-06-06 | 2003-12-24 | Schering Ag | Verwendung von oral verfügbaren Prostacyclinderivaten für die Herstellung eines Arzneimittels zur Behandlung von Krankheiten, die mit Knochenmarködemen assoziiert sind |
CA2554018A1 (en) * | 2004-03-04 | 2005-09-29 | Wyeth | Lyophilization method to improve excipient crystallization |
HUE026166T2 (en) | 2006-02-03 | 2016-05-30 | Actelion Pharmaceuticals Ltd | New epoprosthenol preparation and procedure |
-
2007
- 2007-02-02 HU HUE07763188A patent/HUE026166T2/en unknown
- 2007-02-02 PT PT77631885T patent/PT1993557E/pt unknown
- 2007-02-02 JP JP2008553381A patent/JP5415771B2/ja active Active
- 2007-02-02 CA CA2868998A patent/CA2868998A1/en not_active Abandoned
- 2007-02-02 EP EP07763188.5A patent/EP1993557B1/en not_active Revoked
- 2007-02-02 WO PCT/US2007/002948 patent/WO2007092343A2/en active Application Filing
- 2007-02-02 KR KR1020087021569A patent/KR101351668B1/ko active IP Right Grant
- 2007-02-02 BR BRPI0707488A patent/BRPI0707488B8/pt active IP Right Grant
- 2007-02-02 CN CN2007800113953A patent/CN101410119B/zh active Active
- 2007-02-02 PL PL07763188T patent/PL1993557T3/pl unknown
- 2007-02-02 US US12/278,061 patent/US8318802B2/en active Active
- 2007-02-02 DK DK07763188.5T patent/DK1993557T3/en active
- 2007-02-02 ES ES07763188.5T patent/ES2558705T3/es active Active
- 2007-02-02 SI SI200731721T patent/SI1993557T1/sl unknown
- 2007-02-02 CA CA2641393A patent/CA2641393C/en active Active
-
2012
- 2012-09-17 US US13/621,489 patent/US8598227B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
DK1993557T3 (en) | 2015-12-07 |
US20130018093A1 (en) | 2013-01-17 |
CN101410119A (zh) | 2009-04-15 |
KR101351668B1 (ko) | 2014-01-14 |
US20090088468A1 (en) | 2009-04-02 |
PT1993557E (pt) | 2016-02-10 |
HUE026166T2 (en) | 2016-05-30 |
CA2641393A1 (en) | 2007-08-16 |
PL1993557T3 (pl) | 2016-05-31 |
EP1993557A2 (en) | 2008-11-26 |
CN101410119B (zh) | 2012-03-07 |
US8598227B2 (en) | 2013-12-03 |
SI1993557T1 (sl) | 2016-01-29 |
BRPI0707488B1 (pt) | 2020-05-26 |
BRPI0707488B8 (pt) | 2021-05-25 |
WO2007092343A2 (en) | 2007-08-16 |
JP2009525344A (ja) | 2009-07-09 |
CA2868998A1 (en) | 2007-08-16 |
US8318802B2 (en) | 2012-11-27 |
EP1993557B1 (en) | 2015-11-11 |
KR20090004867A (ko) | 2009-01-12 |
CA2641393C (en) | 2014-12-16 |
EP1993557A4 (en) | 2012-07-25 |
BRPI0707488A2 (pt) | 2011-05-03 |
ES2558705T3 (es) | 2016-02-08 |
WO2007092343A3 (en) | 2008-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5415771B2 (ja) | 新規なエポプロステノール製剤およびその製造方法 | |
NL193307C (nl) | Bruispreparaat met analgetische werkzaamheid. | |
JP6182262B2 (ja) | 抗がん剤を含む安定な水溶性医薬組成物 | |
JP2007500191A (ja) | Cci−779の凍結乾燥処方 | |
JPWO2008020584A1 (ja) | 安定な凍結乾燥製剤 | |
AU2007246046A1 (en) | Pharmaceutical composition comprising high concentrate of polydatin | |
KR100700963B1 (ko) | 켐토테신의 다당체 유도체를 함유하는 동결건조된 액상제제 | |
JP4142149B2 (ja) | バンコマイシンの凍結乾燥製剤 | |
JP2022523712A (ja) | 治療用化合物および組成物 | |
JP3726255B2 (ja) | 安定な凍結乾燥済みチオテパ組成物 | |
JP4326148B2 (ja) | ダルホプリスチンおよびキヌプリスチンに基づく医薬組成物ならびに調製 | |
RU2423130C2 (ru) | Композиция, содержащая эпопростенол, и способ ее получения | |
JP4278115B2 (ja) | キヌプリスチン及びダルホプリスチンに基づく安定化された製薬学的組成物並びにそれらの製造 | |
US20060252804A1 (en) | Flupirtin injectable galenic form | |
CN111796043B (zh) | 注射用盐酸罂粟碱粉针剂及其质量检测方法 | |
AU2021245379A1 (en) | Active substances for medical use | |
CN111065398A (zh) | 用于治疗急性心肌梗塞的、具有乙酰水杨酸与柠檬酸、碳酸氢钠和l-茶氨酸的水溶性共晶的舌下制剂 | |
JP3421330B2 (ja) | ビダラビン注射用乾燥製剤 | |
KR20220163413A (ko) | 제약 제제 아드레노메둘린의 폴리에틸렌 글리콜계 전구약물 및 용도 | |
CN115697318A (zh) | 医用活性物质 | |
WO2022215045A1 (en) | Lyophilized composition comprising selexipag | |
TW202228717A (zh) | 源自福沙吡坦注射劑稀釋液的細胞毒性抑制劑、源自福沙吡坦注射劑稀釋液的細胞毒性的抑制方法、對等張化有效的量的葡萄糖的用途、福沙吡坦注射用水溶液劑的用途、以及細胞毒性得到抑制的福沙吡坦注射用水溶液劑的製造方法 | |
JP2018012660A (ja) | ボルテゾミブを含有する医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20090907 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090908 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100201 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100201 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20100201 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101015 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120808 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121031 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130904 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130917 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131030 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131114 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5415771 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |